Mu receptor agonists are minimally effective in controlling the chronic pain of TOS, producing a generalized numbness, but little amelioration of the more intense symptoms. This is characteristic of neuropathic/neurogenic disorders [16]. Interestingly, nalbuphine, a kappa and sigma agonist, is consistently more effective and has minimal side effects.